Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.66 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470152 | 0.91 | KCNN4 (0.56) | KCNN4DRD2PDE3BPDE3APARP1 | |
| SCHEMBL29353607 | 0.85 | KCNN4 (0.72) | KCNN4DRD2RORCLMNAPOLB | |
| SCHEMBL29353666 | 0.85 | KCNN4 (0.78) | KCNN4 | |
| SCHEMBL29358422 | 0.84 | KCNN4 (0.65) | KCNN4CACNA1BCACNA1CRORC | |
| SCHEMBL22470518 | 0.83 | KCNN4 (0.72) | KCNN4 | |
| SCHEMBL29353715 | 0.80 | KCNN4 (1.00) | KCNN4 | |
| SCHEMBL29353670 | 0.79 | KCNN4 (0.79) | KCNN4 | |
| SCHEMBL29356961 | 0.78 | KCNN4 (0.60) | KCNN4RORC | |
| SCHEMBL29358542 | 0.78 | KCNN4 (0.60) | KCNN4RORC | |
| SCHEMBL30916799 | 0.78 | KCNN4 (0.74) | KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-12391644-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3941903-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2025-07-16 | — | — | EP | disclosed |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2024-11-07 | — | — | US | disclosed |
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391644-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885DRD2 3545/4885PDE3B 864/4885 |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885DRD2 3915/4885PDE3B 686/4885 |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885DRD2 3915/4885PDE3B 686/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885DRD2 3545/4885PDE3B 864/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | KCNN4 43/4885DRD2 3193/4885PDE3B 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.